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Background
Clinical data, especially long-term follow-up, is limited
in CAPS due to its extreme rarity. We report here the
design of a global observational registry for canakinu-
mab (Ilaris
®). The registry is monitored by an external
steering committee with expertise in auto-inflammatory
disease and registry design.
Aim
The primary objective is to monitor overall safety of
routine care with canakinumab in a large cohort
(N≥400) of CAPS patients. Secondary objectives include
exploring growth and development patterns in children
and to measure the long-term impact of canakinumab
on disease progression.
Methods
CAPS patients receiving canakinumab as part of their
routine care are included in this study for a minimum
of 5-years follow-up. Data from routine clinic assess-
ments is supplied at 6-monthly intervals via a web-based
application. Selected safety events potentially associated
with anti-IL-1 therapy such as serious infections, malig-
nancies, hypersensitivity and disease activity/progression
is analyzed. Signs and symptoms of systemic inflamma-
tion, neurologic and ophthalmologic status and the
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Table 1
FCAS (n=10) MWS (n=37) NOMID (n=6) Other (n-5)
Age <4 years 0 2 1 1
Age 4- <18 years 2 6 3 1
Age ≥18 years 8 29 3 3
Male, n (%) 3 (30.0) 20 (54.1) 3 (50.0) 2 (40.0)
NLRP3 mutation, n (%) 10 (100.0) 35 (94.6) 5 (83.3) 2 (86.7)
Disease duration (months, mean) 550 370 172 64
Rash/arthralgia/headache/conjunctivitis (%) 100/100/50/80 97.3/97.3/78.4/75.7 100/100/93.4/66.6 80/100/20/40
History of anaemia (%) 10 8.1 50 0
Prior SAA value (mean, mg/L) 37 26 47 3
Prior IL-1 inhibitor treatment, n (%) 0 14 (37.8) 1 (16.1) 2 (40)
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sis and to ameliorate sensorineural deafness are
assessed. Patterns of growth/development, pregnancies,
outcomes of vaccination, dosing pattern and tolerability
are ascertained. All patients are followed until the regis-
try ends.
Results
Baseline data from the first 60 CAPS patients, including
15 pediatric patients (age <18 years), enrolled to date,
are presented in table 1.
Conclusion
Baseline characteristics of the 60 patients enrolled to
date demonstrate an expected disease background.
Upon availability of a larger data-set, subanalyses will
yield valuable insights into disease characteristics and
modification properties of canakinumab.
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